Prespecified FLOW subgroup analysis testing whether semaglutide’s kidney and cardiovascular benefits hold with or without baseline SGLT2 inhibitor use. PICO summary and expert commentary.
Browsing: Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
An exploratory imaging substudy of a 32-week randomised trial finds semaglutide and empagliflozin each lower cortical apparent diffusion coefficient and reduce total kidney volume in type 2 diabetes. PICO summary and expert commentary.
PIONEER 11 found that oral semaglutide monotherapy lowered HbA1c at all doses versus placebo in drug-naive, predominantly Chinese adults with type 2 diabetes, with weight reduction confined to the 7 mg and 14 mg doses. PICO summary and expert commentary.
Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for…
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide…
A post-hoc pooled analysis of four semaglutide trials reports fewer worsening heart failure events in participants with HFpEF, with no significant effect on cardiovascular death. PICO summary and expert commentary.
A prespecified analysis of the FLOW randomised trial found once-weekly semaglutide reduced heart failure events and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified mortality analysis of the SELECT trial found that semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows semaglutide 2.4 mg improves symptoms, weight, and exercise capacity in obesity-related HFpEF consistently across baseline C-reactive protein strata. PICO summary and expert commentary.
Prespecified subgroup analysis of the pooled STEP-HFpEF Program testing whether atrial fibrillation modifies semaglutide’s effect on symptoms in obesity-related HFpEF. PICO summary and expert commentary.